These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28642029)

  • 1. Azobenzene-containing photoswitchable proteasome inhibitors with selective activity and cellular toxicity.
    Blanco B; Palasis KA; Adwal A; Callen DF; Abell AD
    Bioorg Med Chem; 2017 Oct; 25(19):5050-5054. PubMed ID: 28642029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibitors with photocontrolled activity.
    Hansen MJ; Velema WA; de Bruin G; Overkleeft HS; Szymanski W; Feringa BL
    Chembiochem; 2014 Sep; 15(14):2053-7. PubMed ID: 25125335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome.
    Sun Q; Zhou T; Xi D; Li X; Lü Z; Xu F; Wang C; Niu Y; Xu P
    Eur J Med Chem; 2020 Apr; 192():112160. PubMed ID: 32146375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
    Troiano V; Scarbaci K; Ettari R; Micale N; Cerchia C; Pinto A; Schirmeister T; Novellino E; Grasso S; Lavecchia A; Zappalà M
    Eur J Med Chem; 2014 Aug; 83():1-14. PubMed ID: 24946214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, Synthesis, and Biological Activity of Isosyringolin A.
    Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S
    Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Photoresponsive azo-combretastatin A-4 analogues.
    Rastogi SK; Zhao Z; Barrett SL; Shelton SD; Zafferani M; Anderson HE; Blumenthal MO; Jones LR; Wang L; Li X; Streu CN; Du L; Brittain WJ
    Eur J Med Chem; 2018 Jan; 143():1-7. PubMed ID: 29172077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
    Berkers CR; Leestemaker Y; Schuurman KG; Ruggeri B; Jones-Bolin S; Williams M; Ovaa H
    Mol Pharm; 2012 May; 9(5):1126-35. PubMed ID: 22432738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine.
    Jorda R; Dušek J; Řezníčková E; Pauk K; Magar PP; Imramovský A; Kryštof V
    Eur J Med Chem; 2017 Jul; 135():142-158. PubMed ID: 28441582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, bioactivity, docking and molecular dynamics studies of furan-based peptides as 20S proteasome inhibitors.
    Sun Q; Xu B; Niu Y; Xu F; Liang L; Wang C; Yu J; Yan G; Wang W; Jin H; Xu P
    ChemMedChem; 2015 Mar; 10(3):498-510. PubMed ID: 25641789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors.
    Scotti A; Trapella C; Ferretti V; Gallerani E; Gavioli R; Marastoni M
    J Enzyme Inhib Med Chem; 2016; 31(3):456-63. PubMed ID: 25942361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
    Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
    ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Terminal functionalized thiourea-containing dipeptides as multidrug-resistance reversers that target 20S proteasome and cell proliferation.
    Qin JM; Huang RZ; Yao GY; Liao ZX; Pan YM; Wang HS
    Eur J Med Chem; 2017 Jan; 126():259-269. PubMed ID: 27889629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation.
    Weyburne ES; Wilkins OM; Sha Z; Williams DA; Pletnev AA; de Bruin G; Overkleeft HS; Goldberg AL; Cole MD; Kisselev AF
    Cell Chem Biol; 2017 Feb; 24(2):218-230. PubMed ID: 28132893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
    Zhang J; Cao J; Xu L; Zhou Y; Liu T; Li J; Hu Y
    Bioorg Med Chem; 2014 Jun; 22(11):2955-65. PubMed ID: 24767818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photopharmacological Control of Cyclic Antimicrobial Peptides.
    Yeoh YQ; Yu J; Polyak SW; Horsley JR; Abell AD
    Chembiochem; 2018 Dec; 19(24):2591-2597. PubMed ID: 30324702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
    Niroula D; Hallada LP; Le Chapelain C; Ganegamage SK; Dotson D; Rogelj S; Groll M; Tello-Aburto R
    Eur J Med Chem; 2018 Sep; 157():962-977. PubMed ID: 30165344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
    Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
    Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
    Ge Y; Li A; Wu J; Feng H; Wang L; Liu H; Xu Y; Xu Q; Zhao L; Li Y
    Eur J Med Chem; 2017 Mar; 128():180-191. PubMed ID: 28182990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amino- and chloro-8-hydroxyquinolines and their copper complexes as proteasome inhibitors and antiproliferative agents.
    Oliveri V; Lanza V; Milardi D; Viale M; Maric I; Sgarlata C; Vecchio G
    Metallomics; 2017 Oct; 9(10):1439-1446. PubMed ID: 28932850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photoswitchable Azo- and Diazocine-Functionalized Derivatives of the VEGFR-2 Inhibitor Axitinib.
    Heintze L; Schmidt D; Rodat T; Witt L; Ewert J; Kriegs M; Herges R; Peifer C
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.